Categories: News

Cannara Announces Grant of Options and RSUs

MONTREAL, Sept. 01, 2025 (GLOBE NEWSWIRE) — Cannara Biotech Inc. (“Cannara”, “the Company”, “us” or “we”) (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis products at disruptive prices with two mega facilities based in Québec spanning over 1,650,000 sq. ft., today announced that its board of directors has approved the grant of incentive awards under the Company’s stock option plan (the “Stock Option Plan”), and restricted share unit compensation plan (the “RSU Plan”) (collectively, the “Incentive Plans”).

The awards were granted aligning with the completion of the Company’s fiscal year-end on August 31, 2025, which marked five consecutive years of commercial operations and year-over-year revenue growth since launching its cannabis business.

In accordance with and subject to the terms of the Incentive Plans and the applicable requirements of the TSX Venture Exchange (the “TSXV”), the Company has granted, effective August 28, 2025:

  • 3,625,000 stock options to certain employees of the Company. Each stock option is exercisable into one common share of the Company at an exercise price of $1.44 per share, will vest in equal monthly installments over a period of three (3) years, and will expire ten (10) years from the date of grant.
  • 145,000 restricted share units (RSUs) to members of the board of directors. Each RSU entitles the holder to receive one common share of the Company without additional consideration and will vest in full on the second anniversary of the date of grant.

The grants are subject to the terms of the Incentive Plans and the applicable requirements of the TSXV.

CONTACT

Nicholas Sosiak, CPA, CA
Chief Financial Officer
nick@cannara.ca 
Zohar Krivorot 
President & Chief Executive Officer 
zohar@cannara.ca 


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

ABOUT CANNARA

Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0), is a vertically integrated producer of affordable premium-grade cannabis products for the Canadian markets. Cannara owns two mega facilities based in Québec spanning over 1,650,000 sq. ft., providing the Company with 100,000 kg of potential annualized cultivation output. Leveraging Québec’s low electricity costs, Cannara’s facilities produce premium-grade cannabis products at an affordable price. For more information, please visit cannara.ca.

Staff

Recent Posts

Is SynergyRx GLP-1 Legitimate? Platform Lists Compounded Semaglutide at $200 With Oral Tablet Options

Telehealth Provider Offers FDA-Approved and Compounded Weight Loss Medications in All 50 States, Subject to…

13 hours ago

Direct Meds GLP-1 Medications Platform Maintains LegitScript Certification as New Year Weight Loss Interest Peaks Amid Compounding Regulatory Shifts

Telehealth Platform Facilitates Compounded Semaglutide and Tirzepatide Access Through Licensed Provider Evaluation as FDA Shortage…

13 hours ago

Best Peptides for Boosting Growth Hormone: ReadyRx Lists Prescription Sermorelin in Injectable and Needle-Free Formats for 2026

Analysis examines best peptides for boosting growth hormone as ReadyRx lists prescription sermorelin in injectable…

13 hours ago

Best Fat Burner For Men 2026: Effective Fat Burning Supplements For Men’s Belly Fat Launched By Wolfson Brands Ltd

Discover the best fat burner for men in 2025. Explore Wolfson Brand’s effective fat-burning supplements…

13 hours ago

MEDIROM Partners with World

Deploying “Proof of Human” Infrastructure throughout Japan, a Technology Envisioned by Sam Altman and Alex…

13 hours ago